ClinicalTrials.gg
CompletedNCT04894435MOSAICUpdated Nov 10, 2026

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

A Phase 2 interventional study of mRNA-1273 SARS-CoV-2 vaccine and BNT162b2 in COVID-19, sponsored by Canadian Immunization Research Network. Completed at 8 sites in Canada. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Canadian Immunization Research Network · Phase 2, Interventional, and Prevention

How we know

Updated Nov 10, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 36 under way, 8 of them phase 3. COVID-19 · Canada.

Enrollment
40th of 200
669 · median 120
Started
2021
with 94 others
Phase 2
28 of 289
3 open now
Registered
189th of 289
by date

Among the 289 studies in COVID-19 with a site in Canada, this one is the 40th largest by enrollment of the 200 interventional ones that give a count, is one of 95 that started in 2021, is one of 28 in phase 2, and was the 189th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in COVID-19 with a site in Canada, or all of them as a file.
02

Study summary

The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.

Read the detailed description

For dose 1 and 2, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) are two dose vaccines which were studied in schedules of either 0 and 21 days or 0 and 28 days, respectively. The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to be given in two doses one month to 12 weeks apart. We will compare the interval 0, 28 days to a 0, 112 days (16 weeks) schedule, and assess the immunogenicity of both heterogeneous and heterologous second doses using the Canadian schedule.

For dose 3, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 6 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

For dose 4, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 3 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • SARS-CoV-2
  • vaccine
  • clinical trial
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is willing and able to give written to participate in the study
  2. Age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment
  3. Able and willing to complete all the scheduled study procedures during the whole study follow-up period
  4. If female of and heterosexually active, has practiced adequate for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the final dose of study vaccine (Please refer to the definition section for a description of child-bearing potential and adequate contraception)
  5. MOSAIC-1 Vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized COVID-19 vaccine in the 55 days prior to Visit 1 (documentation of receipt required)
  6. MOSAIC -1 Vaccine naïve subgroups: have not received an authorized COVID-19 vaccine at any time
  7. MOSAIC-2 participants have received two doses of COVID-19 vaccines authorized in Canada ≥6 months prior to study vaccine administration (documentation of receipt required)
  8. MOSAIC-3 participants have received three doses of COVID-19 vaccines authorized in Canada ≥3 months prior to study vaccine administration (documentation of receipt required)

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness of participant or legally acceptable representative to give written
  2. Any confirmed or suspected or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral (≤14 days duration) or topical steroids
  3. Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)
  4. Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine
  5. Allergy to any study vaccine or any active substance in a study vaccine
  6. Bleeding disorder or history of significant bleeding following IM injections or venipuncture
  7. Continuous use of anticoagulants
  8. A history of anaphylaxis to a previous vaccine
  9. Pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine
  10. MOSAIC-1: History of laboratory-confirmed COVID-19 disease prior to enrolment by participant report
  11. Administration of a within 4 weeks prior to study vaccine receipt.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
669 participants (actual)

Study arms

  • Active comparator
    Group 1: Moderna, Moderna - 28 Days apart

    Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Other: 0, 28 day schedule

  • Active comparator
    Group 2: Moderna, Moderna - 112 days apart

    Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Other: 0, 112 day schedule

  • Active comparator
    Group 3: Moderna, Pfizer/BioNTech - 28 days apart

    Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: BNT162b2 · Other: 0, 28 day schedule

  • Active comparator
    Group 4: Moderna, Pfizer/BioNTech - 112 days apart

    Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: BNT162b2 · Other: 0, 112 day schedule

  • Active comparator
    Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart

    Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: BNT162b2 · Other: 0, 28 day schedule

  • Active comparator
    Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart

    Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: BNT162b2 · Other: 0, 112 day schedule

  • Active comparator
    Group 7: Pfizer/BioNTech, Moderna - 28 days apart

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: BNT162b2 · Other: 0, 28 day schedule

  • Active comparator
    Group 8: Pfizer/BioNTech, Moderna - 112 days apart

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: BNT162b2 · Other: 0, 112 day schedule

  • Active comparator
    Group 9: Astra Zeneca, Moderna - 28 days apart

    Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: ChAdOx1-S [recombinant] · Other: 0, 28 day schedule

  • Active comparator
    Group 10: Astra Zeneca, Moderna - 112 days apart

    Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: ChAdOx1-S [recombinant] · Other: 0, 112 day schedule

  • Active comparator
    Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart

    Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: BNT162b2 · Biological: ChAdOx1-S [recombinant] · Other: 0, 28 day schedule

  • Active comparator
    Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart

    Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S \[recombinant\] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days. Vaccine-exposed participants will only be blinded to, and receive, the second injection.

    Biological: BNT162b2 · Biological: ChAdOx1-S [recombinant] · Other: 0, 112 day schedule

  • Active comparator
    Group 1b

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

    Biological: BNT162b2

  • Active comparator
    Group 2b

    Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine

  • Active comparator
    Group 3b

    Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine

  • Active comparator
    Group 4b

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

    Biological: BNT162b2

  • Active comparator
    Group 5b

    Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine

  • Active comparator
    Group 6b

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

    Biological: BNT162b2

  • Active comparator
    Group 7b

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

    Biological: BNT162b2

  • Active comparator
    Group 8b

    Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine

  • Experimental
    Group 9b

    Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

    Biological: Covifenz

  • Active comparator
    Group 1c

    Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

    Biological: BNT162b2

  • Active comparator
    Group 2c

    Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

    Biological: Covifenz

  • Active comparator
    Group 3c

    Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine

  • Active comparator
    Group 4c

    Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

    Biological: Covifenz

  • Active comparator
    Group 5c

    Participants will be blinded and receive either one dose (0.3mL) of BNT162b2 or one half dose (0.25mL) of mRNA-1273 via intramuscular injection in the deltoid muscle.

    Biological: mRNA-1273 SARS-CoV-2 vaccine · Biological: BNT162b2

  • Active comparator
    Group 6c

    Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

    Biological: Covifenz

  • Experimental
    Group 7c

    Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

    Biological: Covifenz

Interventions

  • Biological2019-nCoV Vaccine mRNA-1273Studies of 2019-nCoV Vaccine mRNA-12732019-nCoV Vaccine mRNA-1273 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

    Also known as: COVID-19 Vaccine Moderna, Spikevax

  • BiologicalBNT162 VaccineStudies of BNT162 VaccineBNT162 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

    Also known as: Pfizer-BioNTech COVID-19 Vaccine, Comirnaty

  • BiologicalChAdOx1 nCoV-19Studies of ChAdOx1 nCoV-19ChAdOx1 nCoV-19 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

    Also known as: Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria

  • Other0, 28 day schedule

    Second injection administered 28 days post first injection

  • Other0, 112 day schedule

    Second injection administered 112 days post first injection

  • BiologicalCovifenz

    COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

    Also known as: Medicago COVID-19 vaccine

06

What researchers measure

Primary outcomes

  1. Antibody response to SARS-CoV-2 S protein after 2 doses

    The co-primary outcome for the non-inferiority comparison of 0, 28-day schedules with heterologous second dose is the immune response to SARS-CoV-2 at day 56 (28 days after the second dose of vaccine) based on anti-spike antibody titers.

    Time frame: Day 56

  2. Antibody response to SARS-CoV-2 S protein after 2 doses

    The co-primary outcome for the non-inferiority comparison of schedules in which the timing of the second dose of vaccine is different (0, 28 days v 0, 112 days) is the immune response to SARS-CoV-2 at day 140 (28 days after the last dose in the 0, 112 day schedule) based on anti-spike antibody titers.

    Time frame: Day 140

  3. Antibody response to SARS-CoV-2 S protein after 3 doses

    To determine if a vaccination schedule with a heterologous third dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

    Time frame: Day 28

  4. Antibody response to SARS-CoV-2 S protein after 4 doses

    To determine if a vaccination schedule with a heterologous fourth dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

    Time frame: Day 28

Secondary outcomes

  1. Durability of antibody response to SARS-CoV-2 S over 12 months after 2 doses

    Assess durability of immune responses in each study group over 12 months based on anti-spike antibody titers and pseudoneutralization assay.

    Time frame: Baseline and Days 28, 56, 112, 140, 365

  2. Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity (ADCC), Antibody avidity, RNA seq after 2 doses

    Characterization of the immune response to COVID-19 vaccines in schedules with 0, 28 days versus 0, 112 days dosing and heterologous schedules to day 365.

    Time frame: Days 28, 56, 112, 140, 365

  3. Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 2 doses

    Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

    Time frame: From time of first study injection through Day 365.

  4. Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 3 doses

    Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

    Time frame: From time of first study injection through Day 365.

  5. Acceptability of vaccines as determined by participant-completed questionnaire after 2 doses

    Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

    Time frame: Days 56, 140, and 365

  6. Acceptability of vaccines as determined by participant-completed questionnaire after 3 doses

    Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

    Time frame: Days 28, 180

  7. Antibody to SARS-CoV-2 S and N, RBD after 3 doses

    Assess durability of the immune responses in each study group over 12 months after the study vaccine.

    Time frame: Days 180 and 365

  8. Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity after 3 doses

    Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

    Time frame: Day 365

  9. Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 4 doses

    Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

    Time frame: From time of first study injection through Day 365.

  10. Acceptability of vaccines as determined by participant-completed questionnaire after 4 doses

    Four 5 point likert scale type questions asking whether they would want to receive the vaccine again(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), recommend it to a friend(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), whether they were anxious about receiving it(Not at all; A little; Moderately; Very; Extremely), and whether they would prefer a more painful injection if it conferred better protection(Vaccine A; Vaccine B; No preference; Unsure/don't know).

    Time frame: Days 28, 180

  11. Antibody to SARS-CoV-2 S and N, RBD after 4 doses

    Assess durability of the immune responses in each study group over 12 months after the study vaccine.

    Time frame: Days 180 and 365

  12. Antibody dependent cellular cytotoxicity after 4 doses

    Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

    Time frame: Day 365

  13. Pseudoneutralization assay after 4 doses

    Measuring the 50% Neutralization Titer to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

    Time frame: Day 365

  14. T cell testing after 4 doses

    Measuring the number of T cells to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

    Time frame: Day 365

Other outcomes

  1. Exploratory assessment of interval between dose 1 and 2 on immune response after 3 or 4 doses

    Assess the role of intervals between first and second doses of the primary immunization schedule, and between 2nd and 3rd doses, on immune responses after the third dose over the study period.

    Time frame: From time of first study injection through Day 365.

07

Study locations

8 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2022, 13 months.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 13 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start May 2021 → Jun 2021, primary completion Nov 2024 → Jul 2022 and completion Aug 2025 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2021
First posted
May 20, 2021
StartActual
Jun 11, 2021was May 2021
Primary completionActual
Jul 25, 2022was Nov 2024
CompletionActual
Jun 16, 2023was Aug 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Canada)
  • McGill University Health Centre Vaccine Study Centre · Montreal, Canada
  • CHU de Québec, Université Laval · Québec, Canada
Show 2 removed
  • McGill University Health Centre Vaccine Study Centre · Montréal, Canada
  • CHU de Québec, Université Laval · Québec City, Canada
Nov 10, 2026
Start date
May 20, 2021→Jun 11, 2021
Nov 10, 2026
Primary completion
Nov 15, 2024→Jul 25, 2022
Nov 10, 2026
Study completion
Aug 1, 2025→Jun 16, 2023 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Canada)
    • McGill University Health Centre Vaccine Study Centre · Montreal, Canada
    • CHU de Québec, Université Laval · Québec, Canada
    Show 2 removed
    • McGill University Health Centre Vaccine Study Centre · Montréal, Canada
    • CHU de Québec, Université Laval · Québec City, Canada
    Start date May 20, 2021→Jun 11, 2021
    Primary completion Nov 15, 2024→Jul 25, 2022
    Study completion Aug 1, 2025→Jun 16, 2023 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04894435
Lead sponsor
Canadian Immunization Research Network
Collaborators
Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Jun 11, 2021
Primary completion
Jul 25, 2022
Completion
Jun 16, 2023
Last update
Nov 10, 2026

Study contacts

Joanne Langley
principal investigator · Dalhousie University/CIRN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion